Activation of Human Tumor-infiltrating Lymphocytes by Monoclonal Antibodies Directed to the CD3 Complex

Deric D. Schoof, Carolyn M. Selleck, Anthony F. Massaro, Sung Eun Jung, Timothy Eberlein

Research output: Contribution to journalArticle

56 Scopus citations

Abstract

We have used high concentrations of recombinant-methionyl human interleukin 2 (rIL-2) for the initial growth and expansion of human tumor-infiltrating lymphocytes (TIL). Early in the life of the TIL bulk culture, cytotoxicity was non-major histocompatibility complex restricted. Under these culture conditions antitumor cytotoxicity was observed to decline with increasing age of the bulk culture. In addition, TIL became refractory to rIL-2-induced expansion. We have used solid-phase anti-CD3 antibodies for TIL activation followed by culture in reduced concentrations of rIL-2 to reactivate TIL previously grown in high concentrations of rIL-2. TIL refractory to rIL-2 in terms of growth and antitumor cytotoxicity proved sensitive to anti-CD3 activation. The use of solid-phase anti-CD3 was also more effective than high concentrations of rIL-2 in the expansion of TIL when used at the start of culture. Finally, TIL could be induced to secrete IL-2 following solid-phase activation with anti-CD3. These data suggest that human TIL are susceptible to activation by signals directed at the CD3 complex of the TIL cell surface.

Original languageEnglish
Pages (from-to)1138-1143
Number of pages6
JournalCancer research
Volume50
Issue number4
StatePublished - Feb 15 1990

Fingerprint Dive into the research topics of 'Activation of Human Tumor-infiltrating Lymphocytes by Monoclonal Antibodies Directed to the CD3 Complex'. Together they form a unique fingerprint.

  • Cite this